Lurasidone: A review of its use in adult patients with bipolar i depression

CNS Drugs

Volumn 29, Issue 3, 2015, Pages 253-263

  Sanford, Mark ^a   Dhillon, Sohita ^a  

^a SPRINGER   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

LITHIUM DERIVATIVE; LURASIDONE; PSYCHOTROPIC AGENT; VALPROIC ACID;

ADULT; BIPOLAR DISORDER; CLINICAL TRIAL (TOPIC); COMBINATION DRUG THERAPY; HUMAN;

ADULT; BIPOLAR DISORDER; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; LITHIUM COMPOUNDS; LURASIDONE HYDROCHLORIDE; PSYCHOTROPIC DRUGS; VALPROIC ACID;

EID: 84939955194     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-015-0234-2     Document Type: Review

References (31)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: Am Psychiatr Assoc; 2000.
2. Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59(6):530-7.
3. Ösby U, Brandt L, Correia N, et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry. 2001;58(9):844-50.
4. Vieta E, Valenti M. Pharmacological management of bipolar depression: acute treatment, maintenance, and prophylaxis. CNS Drugs. 2013;27(7):515-29.
5. Sanford M. Lurasidone: in the treatment of schizophrenia. CNS Drugs. 2013;27(1):67-80.
6. European Medicines Agency. Latuda: summary of product characteristics. http://www.ema.europa.eu. Accessed 11 Feb 2015.
7. Sunovion. Latuda (lurasidone HCl) tablets: US prescribing information. 2013. http://www.latuda.com. Accessed 11 Feb 2015.
8. Sunovion Pharmaceuticals Canada Inc. Latuda (lurasidone hydrochloride): Canadian product monograph. 2014. http://webprod5.hc-sc.gc.ca/dpd-bdpp/index-eng.jsp. Accessed 11 Feb 2015.
9. 1A receptor activity. J Pharmacol Exp Ther. 2010;334(1):171-81.
10. Álamo C, López-Muñoz F, García-García P. The effectiveness of lurasidone as an adjunct to lithium or divalproex in the treatment of bipolar disorder. Expert Rev Neurother. 2014;14(6):593-605.
11. Chiu Y-Y, Ereshefsky L, Preskorn SH, et al. Lurasidone drug-drug interaction studies: a comprehensive review. Drug Metab Drug Interact. 2014;29(3):191-202.
12. Loebel A, Cucchiaro J, Silva R, et al. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171(2):169-77.
13. Loebel A, Cucchiaro J, Silva R, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171(2):160-8.
14. Suppes T, Calabrese J, Silva R, et al. Lurasidone adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study (PREVAIL 3) [abstract no. W147 plus poster]. Neuropsychopharmacology. 2013;38(Suppl 2s).
15. Ketter TA, Sarma K, Silva R, et al. Lurasidone in bipolar I depression: a 24-week, open-label extension study [abstract no. 17 plus poster]. In: Annual Meeting of the American Society of Clinical Psychopharmacology; 2014.
16. Iosifescu DV, Pikalov A, Kroger H, et al. Early sustained response with lurasidone in the treatment of bipolar I depression [abstract no. NR6-053 plus poster]. In: 167th Annual Meeting of the American Psychiatric Association; 2014.
17. Thase ME, Tsai J, Kroger H, et al. Lurasidone treatment for bipolar I depression: effect on core depressive symptoms [abstract no. P-41-009 plus poster]. In: 29th International College of Neuropsychopharmacology World Congress; 2014.
18. Calabrese JR, Ketter TA, Kando J, et al. A post hoc analysis of efficacy and tolerability of lurasidone adjunctive therapy with either lithium or valproate for the treatment of bipolar I depression [abstract no. 92 plus poster]. In: College of Psychiatric and Neurologic Pharmacists Annual Meeting; 2014.
19. McIntyre R, Allen M, Cucchiaro J, et al. Lurasidone for the treatment of bipolar I depression: treatment outcomes in the presence of subsyndromal hypomanic features [abstract plus poster]. In: 9th Annual Neuroscience Educational Institute Psychopharmacology Congress; 2013.
20. Goldberg JF, Pikalov A, Werner P, et al. Lurasidone monotherapy of bipolar depression: influence of baseline thyroid function on treatment response [abstract no. 14 plus poster]. In: Annual Meeting of the American Society of Clinical Psychopharmacology; 2014.
21. Chapel S, Chiu Y, Hsu J, et al. Exposure-response model of lurasidone in patients with bipolar depression [abstract no. NR6-44 plus poster]. In: 167th Annual Meeting of the American Psychiatric Association; 2014.
22. Hirschfeld RMA, Cucchiaro J, Pikalov A, et al. Effect of lurasidone monotherapy or adjunctive therapy on anxiety symptoms in patients with bipolar I depression [abstract plus poster]. In: 10th International Conference on Bipolar Disorder; 2013.
23. Ketter TA, Cucchiaro J, Silva R, et al. Lurasidone treatment for bipolar I depression: effects on quality of life and patient functioning [abstract no. NR6-56 plus poster]. In: 167th Annual Meeting of the American Psychiatric Association; 2014.
24. McElroy S, Pikalov A, Cucchiaro J, et al. Short- and longer-term treatment with lurasidone in patients with bipolar I depression: effect on metabolic syndrome [abstract no. P-22-009 plus poster]. In: 29th International College of Neuropsychopharmacology World Congress; 2014.
25. Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2013;15(1):1-44.
26. Sandlin EKL, Gao Y, El-Mallakh RS. Pharmacotherapy of bipolar disorder: current status and emerging options. Clin Pract. 2014;11(1):39-48.
27. Wang WAD, Ansari A, Osser DN. The Psychopharmacology Algorithm Project at the Harvard South Shore Program: 2014 update on bipolar depression [abstract no. P404]. Biol Psychiatry. 2014;1:130S.
28. Pacchiarotti I, Bond DJ, Baldessarini RJ, et al. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry. 2013;170(11):1249-62.
29. Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs. 2002;16(1):23-45.
30. Fagiolini A, Chengappa KNR, Soreca I, et al. Bipolar disorder and the metabolic syndrome: causal factors, psychiatric outcomes and economic burden. CNS Drugs. 2008;22(8):655-69.
31. van Noord C, Strauss SMJM, Sturkenboom MCJM, et al. Psychotropic drugs associated with corrected QT interval prolongation. J Clin Psychopharmacol. 2009;29(1):9-15.